JP2017536409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536409A5 JP2017536409A5 JP2017530034A JP2017530034A JP2017536409A5 JP 2017536409 A5 JP2017536409 A5 JP 2017536409A5 JP 2017530034 A JP2017530034 A JP 2017530034A JP 2017530034 A JP2017530034 A JP 2017530034A JP 2017536409 A5 JP2017536409 A5 JP 2017536409A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazolo
- methyl
- naphthyridin
- butoxy
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000003340 mental effect Effects 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- TXMNAVBOXBRWRL-UHFFFAOYSA-N 1-(2,5-dichlorophenyl)-3,5-dimethylpyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CN1C(=O)C2=C(N(N=C2C)C2=C(Cl)C=CC(Cl)=C2)C2=C1C=CC=N2 TXMNAVBOXBRWRL-UHFFFAOYSA-N 0.000 claims 1
- VFCZPATWIYOHJQ-UHFFFAOYSA-N 1-(2,5-dichlorophenyl)-3-methyl-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CC1=NN(C2=C1C(=O)NC1=C2N=CC=C1)C1=C(Cl)C=CC(Cl)=C1 VFCZPATWIYOHJQ-UHFFFAOYSA-N 0.000 claims 1
- CWYBEKQXIDZGCO-UHFFFAOYSA-N 1-(2-chlorophenyl)-3,5-dimethylpyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CN1C(=O)C2=C(N(N=C2C)C2=C(Cl)C=CC=C2)C2=C1C=CC=N2 CWYBEKQXIDZGCO-UHFFFAOYSA-N 0.000 claims 1
- WQYNZBWUUFOYLZ-UHFFFAOYSA-N 1-(2-chlorophenyl)-3-methyl-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CC1=NN(C2=C1C(=O)NC1=C2N=CC=C1)C1=C(Cl)C=CC=C1 WQYNZBWUUFOYLZ-UHFFFAOYSA-N 0.000 claims 1
- KSGXFQJHUNDYRZ-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-3-methyl-3,3a,5,5a,6,7,8,9,9a,9b-decahydro-2H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CCCCOc1ccc(Cl)c(c1)N1NC(C)C2C1C1NCCCC1NC2=O KSGXFQJHUNDYRZ-UHFFFAOYSA-N 0.000 claims 1
- HLMDAEZBEKMIQP-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-8-chloro-3-methyl-3,3a,5,5a,6,7,8,9,9a,9b-decahydro-2H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CCCCOc1ccc(Cl)c(c1)N1NC(C)C2C1C1NC(Cl)CCC1NC2=O HLMDAEZBEKMIQP-UHFFFAOYSA-N 0.000 claims 1
- CBGSELCUTQWMFO-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-8-methoxy-3-methyl-3,3a,5,5a,6,7,8,9,9a,9b-decahydro-2H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CCCCOc1ccc(Cl)c(c1)N1NC(C)C2C1C1NC(CCC1NC2=O)OC CBGSELCUTQWMFO-UHFFFAOYSA-N 0.000 claims 1
- QDJBJYWUERRLGN-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-3aH-pyrazolo[4,3-h][1,5]naphthyridine-8-carboxamide Chemical compound CCCCOC1=CC(N2N=C(C)C3C2=C2N=C(C=CC2=NC3=O)C(N)=O)=C(F)C=C1 QDJBJYWUERRLGN-UHFFFAOYSA-N 0.000 claims 1
- LZYZEOLAPLNPLJ-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-5H-pyrazolo[4,3-h][1,5]naphthyridine-8-carbonitrile Chemical compound CCCCOC1=CC(N2N=C(C)C3=C2C2=C(NC3=O)C=CC(=N2)C#N)=C(F)C=C1 LZYZEOLAPLNPLJ-UHFFFAOYSA-N 0.000 claims 1
- KCZWAWIWVZBEHK-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-5H-pyrazolo[4,3-h][1,5]naphthyridine-8-carboxylic acid Chemical compound CCCCOC1=CC(N2N=C(C)C3=C2C2=C(NC3=O)C=CC(=N2)C(O)=O)=C(F)C=C1 KCZWAWIWVZBEHK-UHFFFAOYSA-N 0.000 claims 1
- GVCWNUHDYYGLHB-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-3-methyl-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound C(CCC)OC=1C=CC(=C(C=1)N1N=C(C=2C(NC=3C=CC=NC=3C=21)=O)C)F GVCWNUHDYYGLHB-UHFFFAOYSA-N 0.000 claims 1
- SFIZQWYZYMPKTG-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-3-methyl-8-(pyridin-2-ylamino)-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CCCCOC1=CC(N2N=C(C)C3=C2C2=C(NC3=O)C=CC(NC3=NC=CC=C3)=N2)=C(F)C=C1 SFIZQWYZYMPKTG-UHFFFAOYSA-N 0.000 claims 1
- GEWLDLSFZCTLFZ-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-3-methyl-8-pyrazol-1-yl-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CCCCOC1=CC(N2N=C(C)C3=C2C2=C(NC3=O)C=CC(=N2)N2C=CC=N2)=C(F)C=C1 GEWLDLSFZCTLFZ-UHFFFAOYSA-N 0.000 claims 1
- HABNVWFXKMBDEC-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-3-methyl-8-pyrrolidin-1-yl-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CCCCOC1=CC(N2N=C(C)C3=C2C2=C(NC3=O)C=CC(=N2)N2CCCC2)=C(F)C=C1 HABNVWFXKMBDEC-UHFFFAOYSA-N 0.000 claims 1
- OYJBYVZPNLLRDF-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-8-(4-fluorophenoxy)-3-methyl-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CCCCOC1=CC(N2N=C(C)C3=C2C2=C(NC3=O)C=CC(OC3=CC=C(F)C=C3)=N2)=C(F)C=C1 OYJBYVZPNLLRDF-UHFFFAOYSA-N 0.000 claims 1
- IMAOQPNOONDYGN-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-8-(dimethylamino)-3-methyl-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound C(CCC)OC=1C=CC(=C(C=1)N1N=C(C=2C(NC=3C=CC(=NC=3C=21)N(C)C)=O)C)F IMAOQPNOONDYGN-UHFFFAOYSA-N 0.000 claims 1
- MXVWSDWPQOLZHX-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-8-ethylsulfanyl-3-methyl-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound C(CCC)OC=1C=CC(=C(C=1)N1N=C(C=2C(NC=3C=CC(=NC=3C=21)SCC)=O)C)F MXVWSDWPQOLZHX-UHFFFAOYSA-N 0.000 claims 1
- GAJCDBSBYDXXKD-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-N-ethyl-3-methyl-4-oxo-5H-pyrazolo[4,3-h][1,5]naphthyridine-8-carboxamide Chemical compound CCCCOC1=CC(N2N=C(C)C3=C2C2=C(NC3=O)C=CC(=N2)C(=O)NCC)=C(F)C=C1 GAJCDBSBYDXXKD-UHFFFAOYSA-N 0.000 claims 1
- FVKTYFNDUDJLCL-UHFFFAOYSA-N 1-[2-chloro-5-(cyclobutylmethoxy)phenyl]-8-methoxy-3-methyl-3,3a,5,5a,6,7,8,9,9a,9b-decahydro-2H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound COC1CCC2NC(=O)C3C(C)NN(C3C2N1)c1cc(OCC2CCC2)ccc1Cl FVKTYFNDUDJLCL-UHFFFAOYSA-N 0.000 claims 1
- GHKSZQKFAPBQJP-UHFFFAOYSA-N 8-chloro-1-(2,5-dichlorophenyl)-3-methyl-3,3a,5,5a,6,7,8,9,9a,9b-decahydro-2H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CC1NN(C2C1C(=O)NC1CCC(Cl)NC21)c1cc(Cl)ccc1Cl GHKSZQKFAPBQJP-UHFFFAOYSA-N 0.000 claims 1
- LUJYZELYBGDWBN-UHFFFAOYSA-N 8-chloro-1-[2-chloro-5-(cyclopropylmethoxy)phenyl]-3-methyl-5H-pyrazolo[4,3-c][1,5]naphthyridin-4-one Chemical compound CC1=NN(C2=C1C(=O)NC1=C2N=C(Cl)C=C1)C1=C(Cl)C=CC(OCC2CC2)=C1 LUJYZELYBGDWBN-UHFFFAOYSA-N 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 claims 1
- 241000023320 Luma <angiosperm> Species 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 claims 1
- -1 alkyl luma Chemical compound 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- CSYSETGWAJKQLE-UHFFFAOYSA-N ethyl 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-5H-pyrazolo[4,3-h][1,5]naphthyridine-8-carboxylate Chemical compound C(CCC)OC=1C=CC(=C(C=1)N1N=C(C=2C(NC=3C=CC(=NC=3C=21)C(=O)OCC)=O)C)F CSYSETGWAJKQLE-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000005032 impulse control Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088540P | 2014-12-06 | 2014-12-06 | |
| US62/088,540 | 2014-12-06 | ||
| PCT/US2015/064331 WO2016090382A1 (en) | 2014-12-06 | 2015-12-07 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536409A JP2017536409A (ja) | 2017-12-07 |
| JP2017536409A5 true JP2017536409A5 (enExample) | 2019-01-24 |
| JP6608933B2 JP6608933B2 (ja) | 2019-11-20 |
Family
ID=56092609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530034A Expired - Fee Related JP6608933B2 (ja) | 2014-12-06 | 2015-12-07 | 有機化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10105349B2 (enExample) |
| EP (1) | EP3226862B1 (enExample) |
| JP (1) | JP6608933B2 (enExample) |
| KR (1) | KR102562576B1 (enExample) |
| CN (1) | CN107205993B (enExample) |
| AU (1) | AU2015357498B2 (enExample) |
| BR (1) | BR112017012005B1 (enExample) |
| CA (1) | CA2969597C (enExample) |
| HK (2) | HK1243935A1 (enExample) |
| IL (1) | IL252578B (enExample) |
| MX (1) | MX373320B (enExample) |
| RU (1) | RU2702732C1 (enExample) |
| WO (1) | WO2016090382A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9503189B2 (en) | 2014-10-10 | 2016-11-22 | At&T Intellectual Property I, L.P. | Method and apparatus for arranging communication sessions in a communication system |
| WO2016090382A1 (en) * | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9628116B2 (en) | 2015-07-14 | 2017-04-18 | At&T Intellectual Property I, L.P. | Apparatus and methods for transmitting wireless signals |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| IL296734B2 (en) | 2018-04-13 | 2025-06-01 | The Institute Of Cancer Res Royal Cancer Hospital | Bcl6 inhibitors |
| EA202190055A1 (ru) | 2018-06-18 | 2021-04-23 | Янссен Фармацевтика Нв | Производные пиразола в качестве ингибиторов malt1 |
| MX2021008050A (es) | 2019-01-11 | 2021-08-05 | Shionogi & Co | Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2). |
| US12404260B2 (en) | 2019-04-11 | 2025-09-02 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as MALT1 inhibitors |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| CN112851667B (zh) * | 2019-11-28 | 2022-09-09 | 暨南大学 | 含氮并杂环类化合物及其药用组合物和应用 |
| KR20210109406A (ko) | 2020-02-27 | 2021-09-06 | 주식회사 재원인더스트리 | 열 교환기능을 구비한 환기모듈 |
| CN114539263B (zh) * | 2020-11-11 | 2023-04-25 | 暨南大学 | 一类含氮并杂环化合物及其药用组合物和应用 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS571518B2 (enExample) | 1973-10-08 | 1982-01-11 | ||
| US4603203A (en) | 1983-12-14 | 1986-07-29 | Takeda Chemical Industries, Ltd. | 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof |
| CA1251448A (en) | 1985-03-27 | 1989-03-21 | William J. Coates | Pyridazinone derivatives |
| US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
| DK0379917T3 (da) | 1989-01-26 | 1995-12-11 | Bayer Ag | Optisk aktive (meth)acrylsyre-drivater, deres fremstilling, deres polymerisation til optisk aktive polymere og disses anvendelse |
| KR920004437B1 (ko) | 1989-09-12 | 1992-06-05 | 삼성전자 주식회사 | 금전등록기의 거래선 관리방법 |
| NZ238609A (en) | 1990-06-21 | 1993-12-23 | Schering Corp | Polycyclic guanine derivatives; preparation, pharmaceutical compositions, |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| EP0686157A1 (en) | 1993-02-26 | 1995-12-13 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
| DE19541264A1 (de) | 1995-11-06 | 1997-05-07 | Bayer Ag | Purin-6-on-derivate |
| US5824683A (en) | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
| DE19702785A1 (de) | 1997-01-27 | 1998-07-30 | Bayer Ag | Neue cyclische Harnstoffderivate |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US6013621A (en) | 1997-10-17 | 2000-01-11 | The Rockfeller University | Method of treating psychosis and/or hyperactivity |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| DE19931206A1 (de) | 1999-07-07 | 2001-01-11 | Stief Christian | Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung |
| HK1049834A1 (zh) | 1999-10-11 | 2003-05-30 | 辉瑞大药厂 | 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物 |
| IL152925A (en) | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| CZ20023116A3 (cs) * | 2000-03-29 | 2003-01-15 | Altana Pharma Ag | Alkylované imidazopyridinové sloučeniny |
| CN1436080A (zh) | 2000-04-19 | 2003-08-13 | 利利艾科斯有限公司 | 环gmp－特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途 |
| EP1307201B1 (de) | 2000-08-01 | 2004-11-24 | Bayer HealthCare AG | Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung |
| US6887996B2 (en) * | 2000-12-01 | 2005-05-03 | Guilford Pharmaceuticals Inc. | Compounds and their use |
| DE10064105A1 (de) | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| JP4450365B2 (ja) | 2001-08-28 | 2010-04-14 | シェーリング コーポレイション | 多環式グアニンホスホジエステラーゼｖ阻害剤 |
| EP1575916B1 (en) | 2001-08-31 | 2013-05-22 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| CN1585771A (zh) | 2001-11-09 | 2005-02-23 | 先灵公司 | 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂 |
| IL163575A0 (en) | 2002-02-21 | 2005-12-18 | Univ Rockefeller | Compositions and method for regulation of calcium-dependent signalling in brain |
| AU2003288352A1 (en) | 2002-10-30 | 2004-06-07 | Centre National De La Recherche Scientifique (Cnrs) | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| AU2003277562B2 (en) * | 2002-11-06 | 2009-03-26 | Aska Pharmaceutical Co., Ltd. | Pyrazolonaphthyridine derivative |
| HRP20050848A2 (en) | 2003-03-04 | 2006-06-30 | Altana Pharma Ag | Purin-6-one-derivatives |
| EP1613747A1 (en) | 2003-03-31 | 2006-01-11 | Pfizer Products Inc. | Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
| JP2006522151A (ja) | 2003-04-01 | 2006-09-28 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 不妊症におけるホスホジエステラーゼ阻害剤 |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| CA2549510A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| WO2005083069A1 (en) | 2004-01-30 | 2005-09-09 | Pfizer Products Inc. | Pde2 crystal structures for structure based drug design |
| WO2006024640A2 (en) | 2004-09-02 | 2006-03-09 | Altana Pharma Ag | Triazolophthalazines |
| MX2007008137A (es) | 2005-01-05 | 2007-07-19 | Altana Pharma Ag | Triazoloftalazinas como inhibidores de pde2. |
| JP5130053B2 (ja) | 2005-01-05 | 2013-01-30 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | トリアゾロフタラジン |
| WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP1749824A1 (en) | 2005-08-03 | 2007-02-07 | Neuro3D | Benzodiazepine derivatives, their preparation and the therapeutic use thereof |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| WO2007032466A1 (ja) * | 2005-09-15 | 2007-03-22 | Aska Pharmaceutical Co., Ltd. | 複素環化合物、その製造方法並びに用途 |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2007256633B2 (en) | 2006-06-06 | 2013-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008063505A1 (en) | 2006-11-13 | 2008-05-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| PT2152712E (pt) * | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| US7807629B1 (en) | 2007-06-05 | 2010-10-05 | Alcon Research, Ltd. | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma |
| ES2588238T3 (es) | 2007-12-06 | 2016-10-31 | Intra-Cellular Therapies, Inc. | Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico |
| EP2939676A1 (en) | 2007-12-06 | 2015-11-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2010062366A1 (en) | 2008-10-31 | 2010-06-03 | Arginetix, Inc. | Compositions and methods of treating endothelial disorders |
| WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| US20100120763A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| AU2009322899A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| BRPI0922700A2 (pt) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Compostos orgânicos |
| EA201170769A1 (ru) | 2008-12-06 | 2012-02-28 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| MX2011005934A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PE20110922A1 (es) | 2008-12-06 | 2012-01-22 | Intra Cellular Therapies Inc | DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1) |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| WO2011011312A1 (en) | 2009-07-22 | 2011-01-27 | Merck Sharp & Dohme Corp. | Quinolinone pde2 inhibitors |
| US8858911B2 (en) | 2009-10-08 | 2014-10-14 | Intra-Cellular Therapies, Inc. | Phosphodiesterase 1-targeting tracers and methods |
| EP2490693A4 (en) * | 2009-10-19 | 2013-02-27 | Merck Sharp & Dohme | Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| JP5543039B2 (ja) | 2011-02-23 | 2014-07-09 | ファイザー・インク | 神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン |
| KR101626681B1 (ko) | 2011-06-07 | 2016-06-01 | 화이자 인코포레이티드 | 피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도 |
| EP2717877B1 (en) | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP6115962B2 (ja) | 2011-06-27 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ．ベー． | １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体 |
| WO2013034758A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
| WO2013034755A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders |
| US9056863B2 (en) | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| DK2970279T3 (da) | 2013-03-15 | 2020-11-30 | Intra Cellular Therapies Inc | Organiske forbindelser |
| ES2633440T3 (es) * | 2013-03-25 | 2017-09-21 | Sanofi | Derivados de pirazolonaftiridinona como inhibidores de metAP2 (metionina aminopeptidasa 2). |
| US9546175B2 (en) * | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2016090382A1 (en) * | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
-
2015
- 2015-12-07 WO PCT/US2015/064331 patent/WO2016090382A1/en not_active Ceased
- 2015-12-07 CN CN201580073716.7A patent/CN107205993B/zh not_active Expired - Fee Related
- 2015-12-07 HK HK18103466.9A patent/HK1243935A1/zh unknown
- 2015-12-07 HK HK18103143.0A patent/HK1244427A1/zh unknown
- 2015-12-07 BR BR112017012005-4A patent/BR112017012005B1/pt not_active IP Right Cessation
- 2015-12-07 JP JP2017530034A patent/JP6608933B2/ja not_active Expired - Fee Related
- 2015-12-07 AU AU2015357498A patent/AU2015357498B2/en not_active Ceased
- 2015-12-07 EP EP15866060.5A patent/EP3226862B1/en active Active
- 2015-12-07 CA CA2969597A patent/CA2969597C/en active Active
- 2015-12-07 RU RU2017123680A patent/RU2702732C1/ru active
- 2015-12-07 KR KR1020177018725A patent/KR102562576B1/ko active Active
- 2015-12-07 MX MX2017007377A patent/MX373320B/es active IP Right Grant
- 2015-12-07 US US15/533,525 patent/US10105349B2/en active Active
-
2017
- 2017-05-29 IL IL252578A patent/IL252578B/en active IP Right Grant
-
2018
- 2018-09-07 US US16/125,373 patent/US10543194B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| SG10201803812TA (en) | Neuroactive steroids, compositions, and uses thereof | |
| JOP20190143A1 (ar) | مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز | |
| RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
| JP2019512535A5 (enExample) | ||
| JP2014517050A5 (enExample) | ||
| JP2017531020A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| JP2012501327A5 (enExample) | ||
| IN2014CN03234A (enExample) | ||
| JP2014513139A5 (enExample) | ||
| JP2017515863A (ja) | 脊髄性筋萎縮症を処置するための化合物 | |
| EA201101395A1 (ru) | Производные 1-гетероциклил-1,5-дигидропиразоло[3,4d]пиримидин-4-oha и их применение в качестве модуляторов pde9a | |
| JP2016040288A5 (enExample) | ||
| JP2016523907A5 (enExample) | ||
| RU2015140669A (ru) | Пиридинилпиразолохинолиновые соединения | |
| JP2015531764A5 (enExample) | ||
| JP2018012645A (ja) | 新規ジアザビシクロ誘導体 | |
| JP2017513887A5 (enExample) | ||
| JP2008511574A5 (enExample) | ||
| JP2017523201A5 (enExample) | ||
| JP2017536410A5 (enExample) | ||
| CL2007002768A1 (es) | Compuestos derivados de quinolin-amina; proceso de preparacion de dichos compuestos; medicamento; y uso para el tratamiento de enfermedades tales como depresion, trastornos de ansiedad, esquizofrenia, agorafobia, dolor, demencia y enfermedad de parki | |
| JP2019512534A5 (enExample) | ||
| RU2017123686A (ru) | Органические соединения |